Product Description
Peginterferon alfa-2a is used alone or in combination with other medications to treat chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus) in people who show signs of liver damage. Peginterferon alfa-2a is also used to treat chronic hepatitis B infection (swelling of the liver caused by a virus) in people who show signs of liver damage. Peginterferon alfa-2a is in a class of medications called interferons (Sourced from: https://medlineplus.gov/druginfo/meds/a605029.html)
Mechanisms of Action: IFR Inhibitor
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: None
Approved Indications: Hepatitis | Hepatitis, Chronic | Inflammation | Hepatitis B | Hepatitis B, Chronic | Hepatitis C | Hepatitis C, Chronic
Known Adverse Events: Headache | Myalgia | Asthenia
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTIVATE | P2 |
Completed |
HIV Infections |
2022-08-01 |